Range of suitable people: CDEC talked over the uncertainty in the number of sufferers with moderately extreme to extreme hemophilia B in Canada eligible for etranacogene dezaparvovec. Clinical gurus consulted by CADTH indicated that some clients that are categorized as possessing mild or average disorder could possibly have a significant bleeding p